.jpg)
1 hour ago
2
Article content
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has regained exclusive distribution rights for TULSA-PRO® in Canada from Knight Therapeutics Inc. (“Knight”).
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
The TULSA Procedure™, performed using the TULSA-PRO system, is used by physicians to ablate prostate tissue in men suffering from prostate cancer and/or benign prostatic hyperplasia (“BPH”, also known as an enlarged prostate).
Article content
Article content
Article content
Pursuant to an agreement entered into with Knight in April 2015, Knight had acted as Profound’s exclusive distributor for the technology in Canada. Profound has now regained the Canadian TULSA-PRO distribution rights from Knight in return for a one-time cash payment of CDN$90,000 (US$64,000) and a 5% royalty on Canadian Net Sales for 15 years.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“Knight has been a strong supporter of Profound and its groundbreaking TULSA technology for the treatment of prostate disease, including cancer and/or BPH,” said Samira Sakhia, President and CEO of Knight. “Knight’s strategy across Canada and Latin America is to commercialize innovative pharmaceutical products. The launch of TULSA-PRO in Canada, a complex medical device technology, will be served best by Profound’s North American integrated commercial and clinical teams.”
Article content
“Currently, there is just one (but important) Canadian site offering the TULSA Procedure,” commented Profound’s CEO and Chairman, Arun Menawat. “Toronto’s renowned Sunnybrook Health Sciences Centre, the original innovator of the TULSA-PRO technology, has already performed more than 100 TULSA Procedures. Moving forward, as the results of the Level I prostate cancer CAPTAIN trial comparing the TULSA Procedure head-to-head with robotic radical prostatectomy are published in 2026 and beyond, we plan to use them to support our applications to the appropriate Canadian Provincial Health Insurance authorities for coverage. If coverage is approved, we see an even larger opportunity for the TULSA Procedure at Sunnybrook and, indeed, at hospitals across Canada. In the meantime, we also see an opportunity to continue to grow our TULSA-PRO business in Canada via additional sites using the concierge service model on an interim basis.”
Article content
Article content
The TULSA Procedure represents a major advancement in prostate care. Unlike traditional treatments that involve surgery, radiation, or lengthy recovery times, the TULSA Procedure is performed inside an MRI suite using robotically guided, directional ultrasound to precisely ablate targeted prostate tissue — without harming surrounding structures. The TULSA-PRO system — the technology behind the procedure — is the only AI-powered, MRI-guided robotic system for prostate treatment. Real-time thermography from the MRI allows physicians to visualize and control the prostate therapy throughout the procedure and customize treatment for each patient with unmatched precision.
Article content
As user interest in Profound’s technologies continues to build, the Company is deploying its own direct sales team in North America, while partnering with select strategic distribution partners to support the business potential and the customer base in other parts of the world.
Article content
About Profound Medical Corp.
Article content
Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.
English (US)